Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial
Official title:
Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma
RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the
cancer cells.
PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have
refractory or relapsed multiple myeloma.
OBJECTIVES: I. Determine the response rate and response duration of patients with refractory
or relapsed multiple myeloma treated with SU5416. II. Determine the toxicity of SU5416 in
this patient population.
OUTLINE: This is a multicenter study. Patients receive SU5416 IV over 1 hour twice weekly.
Treatment continues in the absence of unacceptable toxicity or disease progression. Patients
are followed for survival.
PROJECTED ACCRUAL: A total of 20-38 patients will be accrued for this study within 2 years.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00568880 -
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT01137825 -
Registry of Older Patients With Cancer
|
||
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00898066 -
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
|
N/A | |
Completed |
NCT00478075 -
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
Completed |
NCT00313625 -
Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma
|
Phase 2 | |
Terminated |
NCT00608517 -
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
|
N/A | |
Completed |
NCT00951626 -
A Standardized Nursing Intervention Protocol for HCT Patients
|
N/A | |
Completed |
NCT00301951 -
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
|
Phase 1 | |
Completed |
NCT00937183 -
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
|
N/A | |
Terminated |
NCT00369291 -
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT00049374 -
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 2 | |
Completed |
NCT00004072 -
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
|
Phase 2 | |
Completed |
NCT00003399 -
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
|
Phase 2 | |
Completed |
NCT00003396 -
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Completed |
NCT00003398 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 4 | |
Active, not recruiting |
NCT00003163 -
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
|
Phase 2 | |
Terminated |
NCT00005641 -
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT00002599 -
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
|
Phase 3 |